Amos 1000
Alternative Names: Amos-1000Latest Information Update: 28 Aug 2020
At a glance
- Originator Ensol Biosciences
- Class Antineoplastics
- Mechanism of Action Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Colorectal-cancer in South Korea
- 26 Jul 2016 Early research in Colorectal cancer in South Korea (unspecified route)